AzTrials
AzTrials

COVID-19Phase 2NCT04890509

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

A Phase 2 study testing Bemcentinib and SoC in people with COVID-19, run by BerGenBio ASA at 12 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COVID-19
What is being tested?
Bemcentinib and SoC
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
115 participants
Where
12 sitesin 2 countries
Study dates
20 Oct 2020to 25 May 2021
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults (greater than or equal to [>=] 18 years) with SARS-CoV-2 infection.
  • Participants with symptoms and/or signs consistent with COVID-19, requiring treatment.
  • A score of Grade 3 to 5 on the 9-point ordinal scale. In India; only Participants with a score of Grade 4 or 5 will be enrolled.
  • a) Male Participants:
  • A male Participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • Female Participants:
Show all 11Show fewer
  • A female Participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
  • Not a woman of childbearing potential. OR
  • A woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
  • Women who are lactating who agree not to breastfeed their child during the study and for at least 120 days after termination of study therapy (they may continue to express milk away from the child during this period, but this milk must be discarded).
  • Ability to provide informed consent signed by the study Participant or legally authorized representative.

Who cannot join

  • Participants who have previously had a score of 6 or 7 on the 9-point ordinal scale.
  • Inability to swallow capsules (administration via nasogastric tube is permitted in Participants who become unable to swallow after starting the study drug).
  • History of the following cardiac conditions:
  • Myocardial infarction within 3 months prior to the first dose
  • Unstable angina
  • History of clinically significant dysrhythmias (long QT features on electrocardiogram [ECG], sustained bradycardia [less than or equal to {<=} 55 beats per minute {bpm}]), left bundle branch block, or ventricular arrhythmia) or history of familial long QT. Participants with an implantable cardioverter defibrillator device in place, will be allowed to enroll. Atrial fibrillation will not be a reason for exclusion.
Show all 20Show fewer
  • Screening 12-lead ECG with a measurable QT interval according to Fridericia correction (QTcF) greater than (>) 470 msec.
  • Clinically significant hypokalaemia.
  • Therapeutic anticoagulation with vitamin K antagonists.
  • Previous bowel resection that would interfere with drug absorption.
  • Any participant whose interests are not best served by study participation, as determined by a senior attending clinician.
  • Alanine aminotransferase/aspartate aminotransferase >5 × the upper limit of normal.
  • Current treatment for human immunodeficiency virus (HIV) or tuberculosis (TB).
  • Positive serologic assay at screening for hepatitis B virus (Hep B surface antigen) or hepatitis C virus (hepatitis C PCR or hepatitis C core antigen) at local laboratory.
  • Stage 4 severe chronic kidney disease.
  • Anticipated transfer to another hospital that is not a study center within 72 hours.
  • Allergy to any study treatment.
  • Experimental off-label usage of medicinal products as treatments for COVID-19 at the time of enrolment.
  • Participants participating in another clinical study of an investigational medicinal product.
  • Current or planned treatment for TB.

Trial locations and contacts

12 sites in 2 countries.

12 sites in 2 countries

India7 sites
  • Kasturba Medical College

    Mangalore, Karnataka, 575001

  • JSS Hospital

    Mysuru, Karnataka, 570 004

  • Chopda Medicare & Research Centre Pvt. Ltd (CMARC) - Magnum Heart Institute

    Nashik, Maharashtra, 422005

  • Maulana Azad Medical College

    New Delhi, 110002

  • Sahyadri Specialty Hospital

    Pune, Maharashtra, 411004

  • Krishna Institute of Medical Sciences (KIMS Hospitals)

    Secunderabad, Telangana, 500003

  • Unity Trauma Center and ICU, Unity Hospital

    Surat, Gujarat, 395002

Other trials in India

South Africa5 sites
  • Tiervlei Trial Centre

    Bellville, Cape Town

  • Into Research

    Groenkloof, Pretoria

  • Lakeview Hospital

    Mowbray, Benoni

  • Vergelegen Mediclinic

    Somerset West, Cape Town

  • Clinical Projects Research

    Worcester

Other trials in South Africa

About this study

Official title: A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).

Conditions
COVID-19
Being tested
Bemcentinib, SoC
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BemcentinibDrug

    Bemcentinib capsules will be administered orally.

  • SoCOther

    The SoC will be administered based on local guidelines.

Study groups in NCT04890509
Study groupRoleWhat they receive
Standard of Care + BemcentinibExperimentalBemcentinib will be administered for up to 15 days, or until discharge from hospital, whichever comes sooner. SoC will be administered based on local guidelines.
Receives: Drug: Bemcentinib; Other: SoC
Standard of CareActive comparatorThe SoC will be administered based on local guidelines in place at the time of treatment during the study.
Receives: Other: SoC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Sustained Clinical Improvement of at Least 2 Points

    Sustained clinical improvement is defined as improvement without subsequent worsening. Time to sustained clinical improvement (in days) from randomization is defined as the number of days to a sustained improvement of at least 2 points on a 9-point category ordinal scale, or live discharge from the hospital, or fit for discharge, whichever occurs first by Day 29. 9-point category ordinal scale: 0-Uninfected, no clinical or virological evidence of infection; 1-Ambulatory, no limitation of activities; 2-Ambulatory, limitation of activities; 3-Hospitalised - mild disease, no oxygen therapy; 4-Hospitalized - mild disease, oxygen by mask or nasal prongs; 5-Hospitalized - severe disease, non-invasive ventilation or high-flow oxygen; 6-Hospitalized - severe disease, intubation and mechanical ventilation; 7-Hospitalized - severe disease, ventilation and additional organ support - vasopressors, renal replacement therapy, extracorporeal membrane oxygenation; 8-Death.

    Measured: From randomization up to Day 29

Secondary outcomes (20)
  1. Percentage of Participants Not Deteriorating According to the Ordinal Scale by 1, 2, or 3 Points

    Percentage of participants not deteriorating according to the 9-point category Ordinal Scale (0= uninfected and 8= Death), by 1, 2, or 3 points was reported. Deterioration by 1, 2 or 3 points at days 2, 8, 15 and 29 is defined as an increase in ordinal scale score of at least 1, 2 or 3 points respectively compared to baseline. Participants who had no ordinal score measured at a Day and who were discharged from hospital prior to that Day had their ordinal score used from the most recent value recorded prior to the Day. Participants who died prior to a Day have a score of 8 used for all Days after death. All other participants with no ordinal score measured at a day are considered to have deterioration at that Day.

    Measured: At Days 2, 8, 15, and 29

  2. Duration of Oxygen Use (in Percentage)

    In this outcome measure percentage of hospitalization days during which oxygen was used is reported. The duration of each occurrence of oxygen use was derived based on the start date and time, and end date and time of the use of any type of supplemental oxygen (including mechanical ventilation) as captured in the electronic case report form (eCRF). For each participant, the duration in days of oxygen use was derived as the sum of the duration (in minutes) of each occurrence of oxygen use, divided by 1440 (24*60).

    Measured: Up to Day 29

  3. Duration of Oxygen-free Days (in Percentage)

    In this outcome measure percentage of hospitalization days which were oxygen-free days was reported.

    Measured: Up to Day 29

  4. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load

    SARS-CoV-2 viral load was determined by polymerase chain reaction (PCR) in oropharyngeal and nasal swab while hospitalized. Baseline is defined as the non-missing measurement taken prior to or on randomization day (including unscheduled measurements, if any).

    Measured: Day 1 (Baseline), 3, 5, 8, 11, 15, and 29

  5. Duration of Ventilation Use (in Percentage) by Hospital Survival Status

    In this outcome measure percentage of hospitalization days during which ventilation was used. Duration of ventilation use by hospital survival status was reported in terms of days. Alive is defined as a participant who did not die whilst in hospital and died is defined as a participant who died whilst in hospital. The duration of ventilation was derived based on the start date and time, and end date and time of either invasive mechanical ventilation or non-invasive mechanical ventilation as the type of supplemental oxygen captured in the eCRF.

    Measured: Up to Day 29

  6. Duration of Ventilation-free Days (in Percentage)- by Hospital Survival Status

    In this outcome measure percentage of hospitalization days which were ventilation-free by hospital survival status was reported. Alive is defined as a participant who did not die whilst in hospital and died is defined as a participant who died whilst in hospital.

    Measured: Up to Day 29

  7. Number of Participants With Any Form of New Ventilation Use

    Number of participants with any form of new ventilation use was reported. New ventilation was defined as either Invasive Mechanical Ventilation or Non-Invasive Mechanical Ventilation as the type of supplemental oxygen captured in the eCRF that was not occurring at the time of randomization.

    Measured: Up to Day 29

  8. Duration of New Ventilation Use (in Percentage) by Hospital Survival Status

    In this outcome measure percentage of hospitalization days during which new ventilation was used. The duration of new ventilation was derived based on the start date and time, and end date and time of either invasive mechanical ventilation or non-invasive mechanical ventilation as the type of supplemental oxygen captured in the eCRF that was not occurring at the time of randomization. Alive is defined as a participant who did not die whilst in hospital and died is defined as a participant who died whilst in hospital.

    Measured: Up to Day 29

  9. Duration of Organ Support (in Percentage)

    In this outcome measure percentage of hospitalization days during which organ support (e.g., including respiratory, renal, and cardiac support) was provided is reported in days. Organ support was approximated from the following adverse events of special interests (AESIs) when treatment was received: Cardiovascular organ failure; Renal organ failure requiring renal replacement therapy; Liver organ failure. For each participant the duration of AESIs was summed, noting that if there are any overlapping dates of AESIs, days were only counted once for a participant.

    Measured: Up to Day 29

  10. Number of Participants With Response

    Response rate was assessed on a 9-point category ordinal scale. Number of participants with response (defined as sustained clinical improvement of at least 2 points (from randomization) on a 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale), whichever comes first) was reported. Participants who were not discharged or who had no ordinal scale assessment on a particular study day (including participants who have died prior to that study day) were considered non-responders.

    Measured: At Days 2, 8, 15, and 29

  11. Time to Live Discharge From the Hospital

    Time to live discharge from the hospital (in days) was calculated from randomization. It was derived as: (date of discharge - date of randomization) +1. Participants who were alive and still in hospital at the time of analysis had their time to discharge censored at the data cut-off date for the analysis. Participants who died at the time of analysis, without having been discharged from hospital, had their time to live discharge censored at Day 29.

    Measured: Up to Day 29

  12. Time to Death

    Time to death (in days) was calculated from randomization. Participants who were not known to have died at the time of analysis had their time to death censored at the last date the participant was known to be alive.

    Measured: Up to Day 60

  13. Overall Mortality

    Number of participants who died were reported.

    Measured: At Days 15, 29, and 60

  14. Change From Baseline in the Ratio of Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2)

    Change from baseline in the ratio of the oxygen saturation to fraction of inspired oxygen concentration (SpO2/FiO2) was measured daily from randomization to Day 15. Baseline is defined as the last non-missing measurement taken prior to randomization (including unscheduled measurements, if any).

    Measured: Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  15. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Measured: Up to Day 90

  16. Duration of Intensive Care Unit (ICU)- (in Percentage)

    In this outcome measure percentage of hospitalization days for which participant was in ICU is reported. Duration of ICU was derived based on start/stop date of admission and start/stop date of ICU stay in the eCRF. Duration of ICU is the sum of duration (days) of each episode of ICU/HDU stay. If a participant died and the stop date of admission is missing, the date of death was used instead.

    Measured: Up to 90 days

  17. Duration of Hospitalization

    Duration of hospitalization (days) was derived based on start/stop date of admission and start/stop date of HDU stay in the eCRF. Duration of hospitalization is derived as stop date of admission minus start date of admission +1. If a participant died and the stop date of admission is missing, the date of death was used instead.

    Measured: Up to 90 days

  18. National Early Warning Score 2 (NEWS2)

    NEWS2 is based on 6 physiological measurements (respiration rate, oxygen saturation [SpO2], systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature). Each of these physiological parameters is rated using a 4-point Likert scale (0= no risk to 3 = high risk). The NEWS2 score is obtained by summing the 6 physiological parameter individual scores, with higher score indicating higher risk of deterioration and need for escalation in clinical care, including transfer of the participant to a higher level of care hospital unit. The NEWS2 score is set to missing if at least 1 physiological parameter individual score is missing, and the overall score is uplifted by 2 points for patients requiring supplemental oxygen to maintain their recommended SpO2. The range of NEWS2 score, taking into account this potential 2 point uplifting, is 0 (best) to 20 (worst).

    Measured: At Days 15 and 29

  19. Time to NEWS2 of <=2, Maintained for at Least 24 Hours

    The NEWS2 is based on is based on 6 physiological measurements. The range of NEWS2 score, is from 0 (best) to 20 (worst). Time to NEWS2 <=2 maintained for at least 24 hours (in days) was calculated from randomization as: The date of the first post-Baseline assessment where NEWS2 is <= 2 and sustained for at least 24 hours ) - date of randomization +1.

    Measured: Up to Day 29

  20. Ranked Trajectory Over 29 Days

    Ranked trajectory is not a scale outcome measure and does not have a validated scale range. It is an evaluation of dynamic changes over time in the ordinal scale (9-point; 0= uninfected to 8= death; higher scores = more severity) of severity based on individual rank. It was calculated over 29 days. Each participant ranks were assigned based on the following order of the ordinal scale, [1] The worst (highest) score, Ascending; [2] The last recorded score, Ascending; [3] The number of days at worst score, Ascending; [4] The best(lowest) score that occurred after the worst score, Ascending; [5] The number of days the participant was at [4], Descending. Orderings performed at steps [2], [3], [4] and [5] were used to resolve any tied ranks resulting from previous step. Each participant had one overall rank for their trajectory. There was no rank range associated, however lower rank = better trajectory.

    Measured: 29 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2021
  2. Study start20 Oct 2020
  3. Primary completion25 May 2021
  4. Study completion25 May 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
115 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04890509
Sponsor's protocol ID
BGBC020
Status last verified
Oct 2024
First submitted
17 May 2021
Last updated
16 Oct 2024
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie the results reported in the article, after deidentification \[text, tables, figures and appendices\].

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Bemcentinib and SoC in people with COVID-19, run by BerGenBio ASA at 12 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in India, South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Oct 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Sustained Clinical Improvement of at Least 2 Points (time frame: From randomization up to Day 29). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in